Applied Genetic Technologies Corp (NASDAQ:AGTC) had its price target increased by BMO Capital Markets from $21.00 to $34.00 in a research report sent to investors on Monday morning. The firm currently has an outperform rating on the stock. Applied Genetic Technologies Corp (NASDAQ:AGTC) stock performance was 6.26% in last session and finished the day at $27.49. Traded volume was 56,787.00million shares in the last session and the average volume of the stock remained 76.49K shares. Applied Genetic Technologies Corp (NASDAQ:AGTC) insider ownership is 10.40%.

Biopharmaceutical company Versartis Inc (NASDAQ:VSAR) has selected Comprehend Systems to help facilitate compilation of real-time study information and subject data. Company is developing VRS-317 a novel long-acting form of recombinant human growth hormone for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections potentially improving compliance and therefore treatment outcomes. The company is currently completing a Phase II clinical trial of VRS-317 in children with GHD. Versartis Inc (NASDAQ:VSAR) rose 6.65 percent to $34.00 Friday on volume of 56,789.00million shares. The intra-day range of the stock was $32.85 to $36.86. Versartis Inc (NASDAQ:VSAR) has a market capitalization of $822.62million.

Orthofix International N.V. (NASDAQ:OFIX) CFO Mark A. Heggestad purchased 13,696 shares of the stock on the open market in a transaction that occurred on Tuesday, June 10th. The stock was purchased at an average cost of $33.25 per share, for a total transaction of $455,392.00. Orthofix International NV (NASDAQ:OFIX)’s stock on June 13, 2014 reported a increase of 0.86% to the closing price of $33.84. Its fifty two weeks range is $19.35 -$33.98. The total market capitalization recorded $623.89million. The overall volume in the last trading session was 137,313.00million shares. In its share capital, OFIX has 18.44million outstanding shares.

Sanford C. Bernstein initiated coverage on shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) in a research report released on Wednesday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. On Friday, shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) advanced 8.77% to close the day at $20.34. Company return on investment (ROI) is 14.50% and its monthly performance is recorded as 102.39%.

Enzo Biochem, Inc. (NYSE:ENZ) is reporting for the quarter ending April 30, 2014. The biomedical (gene) company’s consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.09. This value represents a 40.00% increase compared to the same quarter last year. Enzo Biochem, Inc. (NYSE:ENZ) stock performance was 2.66% in last session and finished the day at $5.02. Traded volume was 310,484.00million shares in the last session and the average volume of the stock remained 272.60K shares. The beta of the stock remained 2.04. Enzo Biochem, Inc. (NYSE:ENZ) insider ownership is 0.30%.